Investment Thesis
Pre-revenue or minimal-revenue pharmaceutical company burning $51.6M in free cash flow with only $11.2M in cash reserves, indicating critical near-term solvency risk and urgent need for capital injection or revenue generation within 2-3 months to continue operations.
Strengths
- Low debt-to-equity ratio of 0.12x demonstrates conservative capital structure and minimal financial leverage
- Strong current ratio of 15.84x indicates adequate working capital relative to current liabilities
- Positive stockholders' equity of $116.8M provides residual asset base and equity cushion
Risks
- Catastrophic cash burn of -$51.6M FCF per period against only $11.2M cash reserves; ~2-3 month operational runway at current burn rate
- Absent or immaterial revenue (N/A reported) combined with -$57.1M net loss indicating pre-commercial or failed development stage
- Deeply negative profitability metrics: -48.9% ROE, -45.5% ROA, and -163.7x interest coverage signal fundamental business failure
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway to insolvency
- Evidence of revenue generation or approved commercial products
- Announcement of capital raise, financing facility, or strategic acquisition
Financial Metrics
Revenue
N/A
Net Income
-57.1M
EPS (Diluted)
$-0.55
Free Cash Flow
-51.6M
Total Assets
125.5M
Cash
11.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-48.9%
ROA
-45.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
15.84x
Quick Ratio
15.82x
Debt/Equity
0.12x
Debt/Assets
6.9%
Interest Coverage
-163.74x
Long-term Debt
14.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T09:06:26.773316 |
Data as of: 2026-03-31 |
Powered by Claude AI